On the basis of studies in preclinical AD-related mouse models and two prior safety and pharmacokinetic studies in healthy human participants (designated as phase 1 and 1b trials), we hypothesized that modulation of p75NTR using LM11A-31 in persons with AD would be well tolerated and would slow AD progression, as measured by biomarkers of synaptic function, degeneration and glial activation (CSF biomarkers, structural magnetic resonance imaging (sMRI) and [18F]-fluorodeoxyglucose positron-emission tomography ([18F]-FDG PET)). Here, NGFR is linked to Alzheimer disease.